Close
Solutions
Online Inquiry
Global Services

ROCK™ Antibody Platform for NK Cell Engagement

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

CAR-NK (Chimeric Antigen Receptor-Natural Killer) therapy has emerged as a promising approach for the treatment of cancer and other diseases. At Creative Biolabs, we are at the forefront of this revolution, offering the innovative ROCK™ Antibody Platform to enhance CAR-NK therapy. This groundbreaking technology leverages the power of natural killer cells in targeting cancer cells, complementing the established CAR-T cell therapy.

ROCK™ Mode of Action

The primary goal of ROCK is to stimulate the body's inherent immune system or natural killer (NK) cells in order to eliminate cancerous cells. What sets our ROCK platform apart is its ability to sidestep the treatment-related side effects typically associated with T cell-based therapies, leading to better patient tolerance. The ROCK platform accomplishes this by utilizing a high-affinity anti-CD16A (also known as Fcγ RIIIa) component, which targets a distinct epitope separate from Fc binding, thereby reducing the risk of competitive binding with circulating plasma Fc. This anti-CD16 component is responsible for enlisting the help of NK cells or macrophages, similar to the role played by the anti-CD3 component in T cell-based bispecific antibodies, but with the focus on activating the innate immune response rather than the adaptive immune response. In summary, ROCK represents a highly specialized and well-suited bispecific platform for engineering NK cell engagers, designed to address some of the limitations associated with current T cell redirection approaches.

ROCK™ Mode of Action.Fig.1 ROCK™ Mode of Action.

Key Features of ROCK™ Antibody Platform

Creative Biolabs' ROCK™ Antibody Platform boasts several distinctive features that set it apart in the field of CAR-NK therapy:

  • CD16A-Specific Antibody Domains for Redirecting Innate Cells:
    Our platform utilizes CD16A-specific antibody domains to redirect innate immune cells effectively.
  • High Affinity and Avidity Binding:
    The high affinity and avidity binding to a unique epitope on CD16A ensures robust engagement of effector cells, even in the presence of competing serum IgG.
  • Versatility in Targeting Different Tumor Entities:
    The ROCK™ platform offers versatility, allowing the development of bispecific or multispecific innate cell engagers to target a wide range of tumor types.
  • Potent Killing of Tumor Cells:
    The platform demonstrates the ability to achieve potent and efficacious killing of tumor cells, regardless of their antigen density, making it highly effective in diverse clinical scenarios.
  • Supported by Clinical Evidence:
    Clinical studies have provided evidence of the safety and efficacy of the ROCK™ platform, further confirming its potential as a promising solution in the field of cancer immunotherapy.

Our Service: Advancing CAR-NK Therapy

Creative Biolabs is committed to advancing CAR-NK therapy with the ROCK™ Antibody Platform. Our comprehensive services encompass every aspect of the development and application of this cutting-edge technology.

  • Custom CAR-NK Development: Our experts collaborate with clients to design and generate custom CAR-NK cells tailored to their specific needs, ensuring the most effective targeting of the chosen antigen.
  • Preclinical Assessment: We conduct rigorous preclinical assessments, including in vitro and in vivo studies, to evaluate the safety and efficacy of CAR-NK therapies developed with the ROCK™ Antibody Platform.
  • Clinical Trials Support: Creative Biolabs offers comprehensive support for clients seeking to transition their CAR-NK therapies into clinical trials, ensuring compliance with regulatory standards and best practices.
  • Research and Development Collaboration: We are open to collaboration with academic and industry partners to further the field of CAR-NK therapy and explore new applications of the ROCK™ Antibody Platform.

Please get in touch with our expert team for more information.

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.